PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Chordate Medical AB

USPTO PatentsView assignee record - 13 granted patents across 3 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61H (PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFI).

Explore the portfolio See the ranking
13
Total patents granted
3
CPC technology areas
16.7
Avg claims per patent
-56%
5-year filing velocity

The verdict

Chordate holds 13 US patents across 3 technology areas, rank #20,902 of 50,000 tracked assignees.

#20,902
of 50,000 US assignees by volume
Top 61%
by Innovation Score (31.9/100)
16.7
avg claims per patent
-56%
filing velocity, last 5 yrs

Portfolio overview

Chordate Medical AB has been granted 13 US utility patents between 2015 and 2024, placing Chordate Medical AB at rank #20,902 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.7 claims per patent with primary concentration in A61H (PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFI). As a Foreign Corporation, Chordate Medical AB is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 31.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 9 in the 2015–2019 window, a -56% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Chordate Medical AB's 16.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Chordate Medical AB against peers pursuing similar technology classes.

How does Chordate compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows Chordate holds 13 patents, placing it at rank #20,902 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Chordate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

32 Top 61% higher than 39% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

0.511.522.533.5 2015201620172018202020222024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Chordate Medical AB patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 7.7%
2016 3 23.1%
2017 3 23.1%
2018 2 15.4%
2020 2 15.4%
2022 1 7.7%
2024 1 7.7%

Which technologies does Chordate Medical AB patent most?

Top 3 of 3 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#20,902

Across all tracked assignees

Innovation Score

31.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Chordate Medical AB hold?
Chordate Medical AB holds 13 US granted patents filed between 2015 and 2024, spanning 3 technology areas.
What is Chordate Medical AB's Innovation Score?
Chordate Medical AB has an Innovation Score of 31.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Chordate Medical AB focus on?
Chordate Medical AB's top technology area is A61H (PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY) with 11 patents. The company has filed patents in 3 CPC subclasses total.
Is Chordate Medical AB's patent filing rate increasing or decreasing?
Chordate Medical AB's recent filing velocity is -56% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Chordate Medical AB's patents?
Chordate Medical AB's patents average 16.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the Chordate Medical AB patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Chordate's 13 grants land it in the top 61% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Chordate ranks #20,902 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61H - see who else leads that technology area. A61H leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

A61H technology

Chordate Medical AB's primary CPC class, all holders and yearly trends
Top 50 patent holders

See where Chordate Medical AB ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.